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Abstract 
Decorative tattooing is a procedure in which exogenous pigment and/or dye is introduced into 
the dermis with the aim of creating a permanent skin decoration. The increasing prevalence of 
tattooed individuals leads to more reported tattoo-related complications. Pseudolymphomat-
ous reaction is a benign reactive proliferation of lymphocytes that may uncommonly occur 
secondary to tattooing. We describe the clinical, histological, and molecular aspects of a pseu-
dolymphomatous reaction to red tattoo pigment. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Case Report 
A 33-year-old woman presented with an itchy, livid red massive infiltrated tumor, sharply 
demarcated and limited to the red part of her red-, black-, and green-colored tattoo 9 months 
after the tattooing procedure (Fig. 1a).  
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The histopathological examination of the lesion revealed pronounced pseudoepitheliom-
atous hyperplasia with spongiosis, and focal necrosis of the epidermis. In the dermis, there 
was an extensive and dense infiltration of small to medium-sized lymphocytes, that spanned 
the epidermis to the deep subcutis with focal epidermotropism and follicular tropism without 
large atypical cells. However, some large activated lymphocytes could be observed in the in-
filtrate. No germinal centers were identified. In addition, granular red pigment deposition and 
eosinophilic infiltration was noticed. The presence of exogenous pigment suggested the cor-
rect diagnosis (Fig. 2a).  
Immunohistological staining of the skin biopsy (Fig. 2b) showed that the majority (>80%) 
of lymphocytes were CD3+, and approximately 50% of all CD3+ cells expressed CD4, and 50% 
expressed CD8 phenotypic markers. Less than 2% of the T cells were positive for CD30; a few 
CD20+ B cells could also be detected in the dermal infiltrate. Less than 5% of all cells expressed 
the proliferation marker Ki-67.  
We detected no clonal rearrangement of the T cell receptor in the polymerase chain reac-
tion (Fig. 3). The differential blood count and all other routine laboratory tests remained 
within the normal range.  
Based on the typical clinical appearance and the pseudolymphomatous histological pat-
tern, we diagnosed the patient with a tattoo-associated pseudolymphomatous reaction to red 
tattoo pigment. 
We treated the lesions topically with mid-potency corticosteroid cream (betamethasone 
valerate) once daily 5 days a week for 6 weeks and every second day for 5 additional months. 
During treatment, we observed gradual regression of the tumors; complete remission of the 
lesions occurred after 6 months of treatment (Fig. 1b). No relapse occurred during a follow-
up period of 3 years. 
Discussion 
Pseudolymphomatous reactions are a heterogeneous group of benign T- or B-cell-rich in-
filtrates which histologically and/or clinically mimic cutaneous lymphoma [1]. Rare cases in 
the literature report the development of pseudolymphomatous reactions induced by tattooing 
[2]. At least 30 cases have been reported, and in most cases, the pseudolymphomatous reac-
tion was related to the intradermal injection of red tattoo pigment [3]. It has been suggested 
that particles in tattoo pigments could act as antigens in the dermal skin layer and induce lym-
phoid cell proliferation, which then leads to a persistent reactive lymphocytic infiltration. 
However, the exact mechanism of the pathogenesis of the pseudolymphoma has yet to be de-
fined [4, 5].  
Like in most of the previously reported tattoo-associated pseudolymphomatous reac-
tions, we also observed mostly T cells in the pseudolymphomatous infiltrate.  
Interestingly, in former reports, the pseudolymphomatous reactions were also mostly 
confined to the red areas of the tattoo [3, 6]. Tattoo ink often contains metal compounds. His-
torically for reddish pigments, mercury (cinnabar) was often applied and has been suggested 
to enhance immunogenicity [3]. Previously, most authors indicated mercury as the causative 
agent [4, 7, 8]. Currently, due to regulations of the Food and Drug Agency (FDA) and the Euro-
pean Agency for the Evaluation of Medicinal Products (EMEA), mercury is prohibited and is 
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no longer of major relevance for the development of pseudolymphomatous and/or allergic 
tattoo reactions. Here, we reported a pseudolymphomatous reaction due to the synthetic azo 
dye (pigment red 210, C20H10CI2N2O2). We identified pigment red 201, C20H10CI2N2O2, 
as a causative agent according to the information about the composition of the applied tattoo 
ink provided by the tattoo ink label and the tattoo studio. As the tattoo studio could not  
provide any ink samples for the further in vitro workup (C20H10CI2N2O2-dependent T cell 
proliferation and activation testing), this information should be used with caution. Tattoo  
ink labelling may be incorrect, and we cannot completely exclude inclusion of additional  
substances, other than C20H10CI2N2O2 or even mercury in the red tattoo pigment used in  
this case.  
Although spontaneous remission of pseudolymphomatous reactions have been reported 
[4], pseudolymphomas are often difficult to treat, and the therapeutic approach is controver-
sial (Table 1). Treatment modalities include topical and intralesional application of glucocor-
ticosteroids as well as surgical excision and laser therapy [7, 9–13]. Additionally, systemic 
therapy with hydroxychloroquine was effective in a case of tattoo-associated pseudolympho-
matous reaction in the green part of the tattoo [8]. 
According to cases reported by other authors, surgical excision of the pseudolymphomat-
ous reaction is the most effective treatment [7, 10, 11, 14–17]. However, surgery may result 
in poor cosmetic outcome and is applicable for small areas only, and therefore its use is lim-
ited. Sepehri et al. [18] have recently suggested dermatome shave as a cosmetically acceptable 
rationale treatment modality for chronic tattoo reactions, as demonstrated in large series. 
Further, laser as treatment option is very disputatious, as some authors claim lasers aggravate 
the contact allergic reaction due to photochemical aspects [13]. In most of the cases reported 
with tattoo-associated pseudolymphomatous reaction limited to the red part of the tattoo, 
treatment with topical or intralesional corticosteroids did not induce remission [5, 12, 19–
22]. In our patient, the pseudolymphomatous lesions resolved completely under topical cor-
ticosteroids. Therefore, we suggest that in the case when the excision of the lesions may be 
limited due to the size of the lesions or cosmetic concerns, therapy with local corticosteroids 
may be tried in first line, despite the high recurrence rates reported in most cases [18]. For 
our patient, the duration of therapy with topical corticosteroids was considerably longer than 
in cases described by other authors. Hence, we propose that a longer duration of treatment 
might be sufficient to induce remission in some cases. The very low efficacy of topical cortico-
steroids reported in the literature might also be influenced by the fact that patients who re-
sponded to topical corticosteroids might be lost for follow-up and therefore not reported. It 
remains very controversial and purely speculative whether pseudolymphomatous reactions 
may rarely transform into malignant lymphoma [8, 23]. We and others would rather suggest 
considering the pseudolymphomatous reactions to tattoo pigment as severely exaggerated 
delayed-type hypersensitivity reactions [13].  
The presented case highlights tattooing, particularly with red ink, as a risk factor for ad-
verse immunological reactions such as cutaneous pseudolymphomatous reactions. These ad-
verse tattooing-related reactions lead to both diagnostic and treatment challenges. 
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Fig. 1. Clinical images of the pseudolymphomatous reaction on the patient’s right lower extremity within 
a red part of her tattoo. a, b A red massive infiltrated tumor sharply demarcated and limited within the red 
part of her red-, black-, and green-colored tattoo 9 months after the tattooing procedure. c, d Complete 
resolution of the pseudolymphomatous reaction 2 years after the initial 6-month treatment with topical 
corticosteroids. 
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Fig. 2. Histopathological and immunohistochemical analyses of a skin biopsy from the red infiltrated part 
of the tattoo on the patient’s right lower leg. a Hematoxylin and eosin (HE): pseudolymphomatous reaction. 
The insert shows the exogeneous red pigment. b CD3 staining: approximately >80% of infiltrate positive. 
c CD4 staining: approximately 50% of infiltrate positive. d CD8 staining: approximately 50% of infiltrate 
positive. e CD30 staining: <2% of infiltrate positive. f CD20 staining: few positive cells. g Ki-67 staining: 
<5% of infiltrate positive. The inserts on pictures b–d represent the higher magnification of a given im-
munohistological staining. 
 
 
 
Fig. 3. Polymerase chain reaction of T cell receptors detected no T cell clonality. 
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Table 1. Treatment outcome in patients with pseudolymphomatous reaction to red pigment tattoo (Pub-
Med) 
      
      
First author [Ref.], year Sex Age,  
years 
Time of  
onset, years 
Therapy Outcome 
      
      
Muñoz [14], 2006 M 36 – Surgical Complete remission  
Jaehn [15], 2014 F 30 00.5 Surgical Complete remission 
Kuo [16], 2011 W 40 .020 Surgical Complete remission 
Marchesi [7], 2012 M 35 00.5 Surgical Complete resolution  
Kahofer [5], 2003 F 34 00.6 Topical corticosteroids No remission 
Surgical Complete remission 
Camilot [17], 2012 F 39 00.4 Surgical No follow-up 
Camilot [17], 2012  M 46 00.3 Surgical No follow-up 
King [11], 2018 M 46 0.15 Surgical Complete resolution 
00.4 Intralesional steroids  Complete remission  
after 1.4 years 
Shin [9], 2009 F 46 00.1 Pulsed dye laser No remission 
Intralesional corticosteroids Recurrence 
            Zinberg [12], 1982 M 28 
 
Intralesional corticosteroids Recurrence 
Cruz [19], 2010 M 30 00.1 Very potent topical corticosteroids No remission 
Malki [20], 2017 M 38 00.2 Medium-potency corticosteroids No remission 
Cristaudo [21], 2012 W 32 00.1 Very potent topical corticosteroids No remission 
Cristaudo [21], 2012 W 36 1.25 Very potent topical corticosteroids No remission 
Cristaudo [21], 2012 M 49 00.2 Very potent topical corticosteroids No remission 
Pasolini [22], 2011 M 34 0.15 Very potent topical corticosteroids No remission 
Tan [10], 2013 F 45 00.3 Potent topical and intralesional  
corticosteroids 
No remission 
Ablative fractional resurfacing followed  
by Q-Switched Nd:YAG 532-nm laser 
Complete remission 
Gutermuth [4], 2007 M 57 00.5 No Complete remission in  
3 years 
      
 
 
 
